New Alzheimer's treatment offered at Seattle's Harborview
The medication, known as lecanemab, or by its brand name Leqembi, is designed for early-onset Alzheimer's patients who have mild cognitive decline.
Stay updated with breaking news from Thomas Grabowski. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The medication, known as lecanemab, or by its brand name Leqembi, is designed for early-onset Alzheimer's patients who have mild cognitive decline.
Hope emerges as Harborview Medical Center administers innovative Alzheimer's drug to first patient. Read more about it.
A Mount Vernon man was the first to receive the new Alzheimers drug, lecanemab, at the UW Medicine's Memory and Brain Wellness Center.
A Mount Vernon man was the first to receive the new Alzheimers drug, lecanemab, at the UW Medicine's Memory and Brain Wellness Center.
Doctors at University of Washington treated their first patient with lecanemab -- a new early Alzheimer's drug shown to slow the brain's cognitive decline, researchers announced.